Pancreatic Cancer Research

ResearcherChristian-Albrechts-Universität zu KielActive in the last 2 years

Tina Daunke

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1062-1076; OpenAlex author ID A5046301692. Sources: OpenAlex.

Their work

Papers
7 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 7

  1. L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the complex tumor stroma Co-author DOI 10.64898/2026.08.10.743835↗
  2. Synergistic Effect of Anti-PD-L1 Treatment and CD8+ T-Cell Activating Nanotherapy in Pancreatic Ductal Adenocarcinoma Evaluated via 3D Mathematical Modeling. First author DOI 10.1097/cji.0000000000000572↗
  3. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2023.1157397↗
  4. Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarci… First author DOI 10.3389/fonc.2023.1160824↗
  5. Biomarkers in Liquid Biopsies for Prediction of Early Liver Metastases in Pancreatic Cancer. Co-author DOI 10.3390/cancers14194605↗
  6. Initiation of Pancreatic Cancer: The Interplay of Hyperglycemia and Macrophages Promotes the Acquisition of Malignancy-Associated Properties in Pancreatic Duct… Co-author DOI 10.3390/ijms22105086↗
  7. Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control. Co-author DOI 10.3390/medsci9030048↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Susanne Sebens · 7 shared papers, 2021–2026 · strength 1.24
  2. Christoph Röcken · 6 shared papers, 2021–2026 · strength 1.11
  3. Silje Beckinger · 6 shared papers, 2021–2026 · strength 1.11
  4. Daniela Wesch · 4 shared papers, 2021–2026 · strength 0.70
  5. H. Schäfer · 4 shared papers, 2021–2023 · strength 0.60
  6. Sascha Rahn · 3 shared papers, 2021–2023 · strength 0.47
  7. Steffen Markus Heckl · 3 shared papers, 2021–2023 · strength 0.47
  8. Anna Maxi Wandmacher · 2 shared papers, 2023–2026 · strength 0.39
  9. Anne‐Sophie Mehdorn · 2 shared papers, 2022–2026 · strength 0.36
  10. Hermann B. Frieboes · 1 shared paper, 2025 · strength 0.28
  11. Dylan A. Goodin · 1 shared paper, 2025 · strength 0.28
  12. Benjamin Heckelmann · 1 shared paper, 2026 · strength 0.23
  13. Rüdiger Braun · 1 shared paper, 2026 · strength 0.23
  14. Annika Bräuer · 1 shared paper, 2026 · strength 0.23
  15. Christian P. Pilarsky · 1 shared paper, 2023 · strength 0.16
  16. Yoshiaki Sunami · 1 shared paper, 2022 · strength 0.13
  17. Florian Bürtin · 1 shared paper, 2022 · strength 0.13
  18. Uwe A. Wittel · 1 shared paper, 2022 · strength 0.13
  19. Christoph Kahlert · 1 shared paper, 2022 · strength 0.13
  20. Faik Güntac Uzunoglu · 1 shared paper, 2022 · strength 0.13
  21. Lilli Otto · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.